Massimo Federici
Overview
Explore the profile of Massimo Federici including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
222
Citations
9511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tavernese A, Cammalleri V, Mollace R, Antonelli G, Piscione M, Cocco N, et al.
J Cardiovasc Dev Dis
. 2025 Jan;
12(1).
PMID: 39852287
Cardiac involvement in cancer is increasingly important in the diagnosis and follow-up of patients. A thorough cardiovascular evaluation using multimodal imaging is crucial to assess any direct cardiac involvement from...
2.
Castera L, Alazawi W, Bugianesi E, Caussy C, Federici M, Romero-Gomez M, et al.
Liver Int
. 2025 Jan;
45(2):e16224.
PMID: 39752213
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe subtype, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and strongly associated with obesity and type 2 diabetes...
3.
Minty M, Germain A, Sun J, Kaglan G, Servant F, Lelouvier B, et al.
Gut Microbes
. 2024 Dec;
17(1):2439105.
PMID: 39714075
Recent sets of evidence have described profiles of 16S rDNA sequences in host tissues, notably in fat pads that are significantly overrepresented and can serve as signatures of metabolic disease....
4.
Antonetti L, Berrilli F, Di Cristanziano V, Farowski F, Daeumer M, Eberhardt K, et al.
Gut Pathog
. 2024 Nov;
16(1):72.
PMID: 39614306
The composition of human gut microbiota is dominated by bacteria which have been extensively studied. The role of intestinal eukaryote microorganisms like Blastocystis, however, remains under investigation. Moreover, the potential...
5.
Longo S, Cicalini I, Pieragostino D, De Laurenzi V, Legramante J, Menghini R, et al.
Biomedicines
. 2024 Nov;
12(11).
PMID: 39595205
This study aims to identify a metabolomic signature that facilitates the classification of syncope and the categorization of the unexplained syncope (US) to aid in its management. We compared a...
6.
Mollace R, Longo S, Nardin M, Tavernese A, Musolino V, Cardamone A, et al.
Diabetes Res Clin Pract
. 2024 Oct;
217:111891.
PMID: 39414088
Metabolic dysfunction-associated steatotic liver disease (MASLD), represents a growing health concern due to its strong association with metabolic syndrome, obesity, and type 2 diabetes mellitus (T2DM). This condition, characterized by...
7.
Marx N, Ryden L, Federici M, Marx-Schutt K, Verket M, Muller-Wieland D, et al.
Eur Heart J
. 2024 Oct;
45(48):5117-5126.
PMID: 39387537
With the increasing burden of diabetes as a cause of macro- and microvascular disease linked to the epidemics of obesity, attention is being paid to dysglycaemic states that predict and...
8.
Castells-Nobau A, Moreno-Navarrete J, de la Vega-Correa L, Puig I, Federici M, Sun J, et al.
Gut
. 2024 Oct;
74(2):229-245.
PMID: 39358003
Background: The microbiota is emerging as a key factor in the predisposition to insulin resistance and obesity. Objective: To understand the interplay among gut microbiota and insulin sensitivity in multiple...
9.
Decreased circulating IPA levels identify subjects with metabolic comorbidities: A multi-omics study
Ballanti M, Antonetti L, Mavilio M, Casagrande V, Moscatelli A, Pietrucci D, et al.
Pharmacol Res
. 2024 May;
204:107207.
PMID: 38734193
In recent years several experimental observations demonstrated that the gut microbiome plays a role in regulating positively or negatively metabolic homeostasis. Indole-3-propionic acid (IPA), a Tryptophan catabolic product mainly produced...
10.
Longo S, Cassandra F, Cardolini I, Montagna M, Nucera A, Federici M
Acta Diabetol
. 2024 Feb;
61(5):671-674.
PMID: 38424212
No abstract available.